Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANRO is 22.18M and currently, short sellers hold a 13.81% of that float. On September 25, 2024, ANRO’s average trading volume was 278.59K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ANRO) stock’s latest price update
Alto Neuroscience Inc. (NYSE: ANRO)’s stock price has dropped by -10.53 in relation to previous closing price of 13.29. Nevertheless, the company has seen a loss of -13.46% in its stock price over the last five trading days. businesswire.com reported 2024-09-03 that MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in September: Alto Investor Day Focused on ALTO-100 in Major Depressive Disorder, September 9th 2024: Ahead of topline data expected in October 2024 f.
ANRO’s Market Performance
Alto Neuroscience Inc. (ANRO) has seen a -13.46% fall in stock performance for the week, with a 4.21% gain in the past month and a 20.83% surge in the past quarter. The volatility ratio for the week is 8.49%, and the volatility levels for the past 30 days are at 7.08% for ANRO. The simple moving average for the past 20 days is -9.22% for ANRO’s stock, with a -11.14% simple moving average for the past 200 days.
Analysts’ Opinion of ANRO
Many brokerage firms have already submitted their reports for ANRO stocks, with Wedbush repeating the rating for ANRO by listing it as a “Outperform.” The predicted price for ANRO in the upcoming period, according to Wedbush is $29 based on the research report published on September 03, 2024 of the current year 2024.
ANRO Trading at -3.04% from the 50-Day Moving Average
After a stumble in the market that brought ANRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.46% of loss for the given period.
Volatility was left at 7.08%, however, over the last 30 days, the volatility rate increased by 8.49%, as shares surge +2.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.00% lower at present.
During the last 5 trading sessions, ANRO fell by -13.46%, in comparison to the 20-day moving average, which settled at $13.11. In addition, Alto Neuroscience Inc. saw -42.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANRO starting from Savitz Adam, who purchase 12,069 shares at the price of $12.60 back on Jul 09 ’24. After this action, Savitz Adam now owns 36,920 shares of Alto Neuroscience Inc., valued at $152,085 using the latest closing price.
Savitz Adam, the CHIEF MEDICAL OFFICER of Alto Neuroscience Inc., purchase 2,931 shares at $13.22 during a trade that took place back on Jul 10 ’24, which means that Savitz Adam is holding 39,851 shares at $38,748 based on the most recent closing price.
Stock Fundamentals for ANRO
Current profitability levels for the company are sitting at:
- -145.73 for the present operating margin
- 0.22 for the gross margin
The net margin for Alto Neuroscience Inc. stands at -133.88. The total capital return value is set at -0.29.
Based on Alto Neuroscience Inc. (ANRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -4.17. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -38.39.
Currently, EBITDA for the company is -37.44 million with net debt to EBITDA at 3.45. When we switch over and look at the enterprise to sales, we see a ratio of 369.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.85.
Conclusion
To wrap up, the performance of Alto Neuroscience Inc. (ANRO) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
